Navigation Links
RZN Nutraceuticals Receives United States Patent & Trademark Office Notice of Allowance for Proprietary HerbaZorb(TM) Absorption and Delivery System Technology Used in Popular Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) Products
Date:9/11/2009

MIAMI, Sept. 11 /PRNewswire/ -- RZN Nutraceuticals, Inc.,(www.rznnutra.com) a leading developer of proven effective herbal products which have been clinically tested on sufferers of severe arthritis and migraines has announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for the firm's absorption and delivery system process methodology patent application, a technology RZN has named HerbaZorb(TM). Two of the firm's most popular product offerings, Arthri-Zen Relief(R) and Migra-Zen Relief(R) PLUS capsules already use the technology in their manufacture. The use of this preparation method ensures the rapid and effective absorption of active ingredients.

"We're very pleased that the U.S. Patent and Trademark Office has recognized HerbaZorb as a patentable delivery system that allows herbal supplements and functional foods to be absorbed with full potency intact," said Mark Lubin, founder of RZN Nutraceuticals, Inc., and a 25-year veteran biomedical engineer and research scientist in the fields of orthopedics, joint diseases, implantable cardiac devices, materials science and medical chemistry.

Among the proprietary characteristics of HerbaZorb noted in the patent application are that it protects beneficial phytochemicals of herbs and herbal extracts from being digested prior to entering the bloodstream, providing a significant advantage to both producers of herbal products and those who consume them. "The basis for our patent is that our delivery system represents a breakthrough in the field of bioavailability, the process by which active ingredients are delivered to the bloodstream intact, ensuring their maximum usefulness in the body." Mr. Lubin commented.

According to company President Robert Hunt, "It is very satisfying to gain this important recognition for HerbaZorb, especially as we continue making the process available to other manufacturers who want us to prepare their herbal ingredients using this new technology."

Clinical researchers have long studied the role absorption plays in the bioavailability of active ingredients ingested into the body. According to the Physician's Desk Reference, only 10 to 20 percent of vitamins and minerals taken orally in tablet form are actually absorbed into the bloodstream.

"My goal has always been to develop the most effective and natural pain relief formulations possible, which resulted in the Arthri-Zen Relief(R) and Migra-Zen Relief(R) PLUS family of products," Mr. Lubin stated. "With the advances in absorption offered by HerbaZorb, we can ensure that everyone in the industry using herbal blends can benefit from maximum bioavailability so the active ingredients in them are utilized most fully by the human body."

RZN Nutraceuticals' products are marketed direct to natural accounts, through private label, catalogue sales, practitioner offices, health clubs and on company's website, www.rznnutra.com. Future distribution plans include national drug store chains and natural supplement outlets.

For more information on Migra-Zen Relief Plus(R) or the three Arthri-Zen Relief(R) formulations, visit www.rznnutra.com, or contact RZN President Robert Hunt 904-213-8232.

For media inquiries, contact Jennifer Bryan of Christie Communications (www.christiecomm.com) at 805-969-3744.


'/>"/>
SOURCE RZN Nutraceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals
2. Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line
3. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
4. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
5. Nutraceuticals could prevent diabetes
6. Berkeley Premium Nutraceuticals Pushes Forward
7. UM receives grant to support graduate students in the family nurse practitioner program
8. Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R)
9. CBM-US Receives $3 Million Grant To Fund HIV/AIDS Prevention and Care Efforts in Africa
10. Solos Endoscopy, Inc. Receives Purchase Order from One of the Major Healthcare Systems in Missouri
11. Ascenta Therapeutics Receives Clearance to Initiate Clinical Trials With AT-406
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: